KRAS and neoplasm: Perhaps the most compelling evidence for a role for DUSP6/MKP-3 as a tumour suppressor has come from studies of pancreatic cancer in which 90% of tumours contain activating mutations in Kras. Although there is no evidence of mutation within the DUSP6 gene, mRNA expression levels are consistently lower in pancreatic cancer cell lines when compared to immortalised normal pancreatic ductal cells [22], [23].